ES2062763T3 - Preparacion farmaceutica de 1-octadecil-2-metil-glicero-3-fosfocolina administrable por via intravenosa. - Google Patents

Preparacion farmaceutica de 1-octadecil-2-metil-glicero-3-fosfocolina administrable por via intravenosa.

Info

Publication number
ES2062763T3
ES2062763T3 ES91902674T ES91902674T ES2062763T3 ES 2062763 T3 ES2062763 T3 ES 2062763T3 ES 91902674 T ES91902674 T ES 91902674T ES 91902674 T ES91902674 T ES 91902674T ES 2062763 T3 ES2062763 T3 ES 2062763T3
Authority
ES
Spain
Prior art keywords
lipophilic
pharmaceutical preparation
och3
emulsion
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902674T
Other languages
English (en)
Inventor
Dieter Wiebecke
Rabbe Nordstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedMark Pharma GmbH
Original Assignee
MedMark Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedMark Pharma GmbH filed Critical MedMark Pharma GmbH
Application granted granted Critical
Publication of ES2062763T3 publication Critical patent/ES2062763T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

CON UN PREPARADO FARMACEUTICO DE ET18 TRACION INTRAVENOSA, QUE ESTA CARACTERIZADO PORQUE CONTIENE UNA EMULSION LIPOFILA DE ACEITE EN AGUA, SE PUEDEN ADMINISTRAR GRANDES DOSIS DEL FARMACO ET18-OCH3 SIN EFECTOS SECUNDARIOS. LAS EMULSIONES LIPOFILAS CONTENIDAS EN ESTE PREPARADO PRESENTAN USUALMENTE PARTICULAS LIPOFILAS DEL TAMAÑO DE QUILOMICRONES. EN EL PREPARADO FARMACEUTICO SE ADMINISTRA USUALMENTE LA SUSTANCIA ACTIVA Y LA EMULSION LIPOFILA SIMULTANEAMENTE DE MODO INTRAVENOSO. NO OBSTANTE, TAMBIEN EN POSIBLE APLICAR LA EMULSION DE ACEITE Y AGUA Y LA SUSTANCIA ACTIVA POR SEPARADO O ESCALONADA TEMPORALMENTE. POR TANTO, TAMBIEN SE DESCRIBE UN PREPARADO FARMACEUTICO EN EL QUE LA SUSTANCIA ACTIVA ET18-OCH3 Y LA EMULSION LIPOFILA ESTAN PRESENTES COMO PREPARADO COMBINADO. ADICIONALMENTE SE DESCRIBE TAMBIEN EL EMPLEO DE ET18-OCH3 Y UNA EMULSION LIPOFILA PARA LA PRODUCCION DE MEDICAMENTOS QUE PRESENTEN UN EFECTO ANTIPROLIFERATIVO Y QUE SE EMPLEEN PARA LA SUPRESION DE REACCIONES INMUNOLOGICAS Y PARA EL TRATAMIENTO DE TUMORES ASI COMO PARA EL TRATAMIENTO DE ESCLEROSIS MULTIPLE Y ENFERMEDADES AUTOINMUNES.
ES91902674T 1990-01-03 1990-12-21 Preparacion farmaceutica de 1-octadecil-2-metil-glicero-3-fosfocolina administrable por via intravenosa. Expired - Lifetime ES2062763T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4000084A DE4000084A1 (de) 1990-01-03 1990-01-03 Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts)

Publications (1)

Publication Number Publication Date
ES2062763T3 true ES2062763T3 (es) 1994-12-16

Family

ID=6397585

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902674T Expired - Lifetime ES2062763T3 (es) 1990-01-03 1990-12-21 Preparacion farmaceutica de 1-octadecil-2-metil-glicero-3-fosfocolina administrable por via intravenosa.

Country Status (7)

Country Link
EP (1) EP0509042B1 (es)
JP (1) JPH05502878A (es)
AT (1) ATE102023T1 (es)
DE (2) DE4000084A1 (es)
DK (1) DK0509042T3 (es)
ES (1) ES2062763T3 (es)
WO (1) WO1991009590A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009769A1 (en) * 1992-11-02 1994-05-11 Buchman Alan L Use of choline in total parenteral nutrition
WO1997004765A1 (en) * 1995-07-25 1997-02-13 Smithkline Beecham Corporation INHIBITION OF CoA-INDEPENDENT TRANSACYLASE AND APOPTOSIS
DE19822509A1 (de) * 1998-05-19 1999-11-25 Medmark Pharma Gmbh Edelfosin zur Behandlung von Hirntumoren
DE19829448A1 (de) * 1998-07-01 2000-10-12 Medmark Pharma Gmbh 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen
US20110110984A1 (en) 2006-11-10 2011-05-12 Alphaptose Gmbh Oral Dosage Form Comprising Tri-Substituted Glycerol Compounds
CA2673040C (en) 2006-12-20 2016-02-02 Universitaetsklinikum Hamburg-Eppendorf Use of tri-substituted glycerol compounds for the treatment of hematological malignancies
WO2008074573A1 (en) * 2006-12-20 2008-06-26 Alphaptose Gmbh Topical dosage form comprising tri-substituted glycerol compounds

Also Published As

Publication number Publication date
JPH05502878A (ja) 1993-05-20
DK0509042T3 (da) 1994-05-09
DE59004838D1 (de) 1994-04-07
ATE102023T1 (de) 1994-03-15
WO1991009590A1 (de) 1991-07-11
EP0509042A1 (de) 1992-10-21
EP0509042B1 (de) 1994-03-02
DE4000084A1 (de) 1991-07-04

Similar Documents

Publication Publication Date Title
Gafni et al. Idiopathic acquired agammaglobulinemia associated with thymoma: report of two cases and review of the literature
DE3686797T2 (de) Emulsionen zur verabreichung in wasser schwerloeslicher ionisierbarer basischer hydrophober arzneistoffe.
Robinson et al. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
DE60036826T2 (de) Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
KOUGH et al. Thymoma associated with erythroid aplasia, bullous skin eruption, and the lupus erythematosus cell phenomenon: report of a case
Valentic et al. Hypercalcemia associated with oral isotretinoin in the treatment of severe acne
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
ES2062763T3 (es) Preparacion farmaceutica de 1-octadecil-2-metil-glicero-3-fosfocolina administrable por via intravenosa.
SE7711102L (sv) Nya medel och nya sett att behandla klimakteriska bortfallsymptom
JPH06279276A (ja) 免疫不全症候群治療の補助療法剤
DE3883208T2 (de) Mittel zur behandlung von keratose.
Acocella et al. Serum and urine concentrations of rifampicin administered by intravenous infusion in man
Berger et al. Pharmacologic studies of beta-endorphin in psychopathology.
Shnider Early human trials with anticancer agents: Dosage schedules and routes of administration
US3429971A (en) Method of treating avian lymphomatosis induced by es4 strain of lymphomatosis virus
Kushner Experience with greater than recommended doses of fluphenazine and triflupromazine
Robertson et al. Toxicity of doxorubicin and methotrexate in osteogenic sarcoma.
Sakurai et al. Liposteroid therapy for chronic childhood idiopathic thrombocytopenic purpura: Two case reports
Richmond et al. Side-effects of Tranylcypromine
JPH0149129B2 (es)
Kazamatsuri et al. Serum Levels of Phenytoin and Phenobarbital in Epileptic Patients treated with Mixture Antiepileptic Tablets, Comital‐L or Hydantol‐F
Cecikas THE TREATMENT OF AMEBIC DYSENTERY WITH IPECAC BY RECTUM
April Isonicotinic Acid Hydrazide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 509042

Country of ref document: ES